Revolutionary Blood Test Predicts breast Cancer Treatment Response with Striking Accuracy
Table of Contents
A new, simple DNA blood test offers the potential to dramatically improve breast cancer treatment by predicting how patients will respond to therapy, possibly sparing them from ineffective regimens and accelerating their path to recovery.
More than two million people worldwide are diagnosed with breast cancer annually, making it the most prevalent form of the disease globally. Despite advancements in treatment, determining the optimal approach for each patient remains a notable challenge. Now, researchers have developed a liquid biopsy capable of forecasting a patient’s likelihood of responding to a specific treatment before it even begins. This breakthrough promises to personalize cancer care and considerably enhance patient outcomes.
Decoding Cancer’s Signals in the Blood
The innovative test, spearheaded by a team at the Institute of Cancer Research, London (ICR), analyzes circulating tumor DNA (ctDNA) – microscopic fragments of cancer DNA released into the bloodstream by tumor cells. By measuring these levels, doctors can gain valuable insights into the disease’s characteristics and its potential vulnerability to various therapies.
researchers assessed ctDNA levels in blood samples collected from 167 patients, both prior to the commencement of treatment and again four weeks later, following a single treatment cycle. The findings were published in Nature Medicine.
The study was conducted at the NIHR Biomedical research Centre at the Royal Marsden NHS foundation trust, and the ICR, focused on patients with advanced breast cancer. Participants were divided into two groups based on their cancer type and genetic mutations.
The first group comprised patients with cancers harboring mutations in ESR1, HER2, AKT1, AKT, or PTEN, who received targeted treatments specifically designed to address those mutations. The second group consisted of individuals with triple-negative breast cancer, an aggressive subtype representing 10-15% of all cases globally and lacking readily targetable mutations. These patients received a combination of the PARP inhibitor olarparib and the ATR inhibitor ceralasertib.
Compelling Data Demonstrates Predictive Power
For patients with triple-negative breast cancer, lower ctDNA levels before treatment initiation were associated with significantly longer progression-free survival – 10.2 months compared to 4.4 months for those with higher levels. Furthermore, 40% of patients with low ctDNA levels experienced a positive treatment response, defined as tumor shrinkage or disappearance, compared to just 9.7% of those with higher levels.
A similar, though less pronounced, correlation between pre-treatment ctDNA levels and clinical outcomes was observed in the first group. Notably, patients in the first group with undetectable ctDNA after just four weeks of treatment exhibited especially favorable outcomes, with their cancer remaining at bay for 10.6 months versus 3.5 months for those whose ctDNA remained detectable.
In the second group, the blood test conducted after four weeks of treatment also demonstrated a strong link between ctDNA levels and patient outcomes. Patients with undetectable ctDNA experienced prolonged disease control – 12 months compared to 4.3 months for those with detectable ctDNA.
“By analyzing circulating tumor DNA in blood samples from patients with advanced breast cancer, we identified a clear link between these levels, both at the start and after one cycle of treatment, and how well patients responded to therapy,” the researcher stated. “these findings support the use of ctDNA as a non-invasive biomarker for predicting outcomes and monitoring treatment response.”
Expanding the Potential of Liquid Biopsies
Professor Nicholas Turner, a professor of molecular oncology at the ICR and a consultant medical oncologist at the Royal Marsden, believes the application of this technology extends beyond advanced breast cancer. “This research looked at advanced breast cancer, but these tests could also work for early-stage breast cancers,” he said.
the liquid biopsy holds the promise of accelerating treatment decisions, personalizing care, and ultimately improving effectiveness. This innovative approach represents a significant step forward in the fight against breast cancer, offering hope for more targeted and prosperous therapies for patients worldwide.
